English
简体中文
Total: £ 56.28
Published Date: 2025-12-26 | Pages: 93 | Tables: 91 | Service & Software
The global market for In Vivo Pharmacology Model was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
In vivo pharmacological modeling is mainly used to study and evaluate the activity, metabolism, distribution, excretion, and pharmacodynamic properties of drugs in organisms. Such models provide important support for drug development, optimization and clinical application by simulating the behavior of drugs in organisms such as animals or humans. In terms of specific applications, in vivo pharmacological modeling involves several fields, such as oncology, neuroscience, and cardiovascular disease. In the field of oncology, researchers study the therapeutic effects of drugs on tumors by establishing tumor models; in the field of neuroscience, researchers use in vivo pharmacology models to study the effects of drugs on the nervous system; in the field of cardiovascular disease researchers use in vivo pharmacology models to assess the effects of drugs on the cardiovascular system and so on.
North American market for In Vivo Pharmacology Model is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for In Vivo Pharmacology Model is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for In Vivo Pharmacology Model in Cardiovascular Diseases is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of In Vivo Pharmacology Model include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt, Sygnature Discovery, Aurigene Pharmaceutical Services Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for In Vivo Pharmacology Model, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding In Vivo Pharmacology Model.
The In Vivo Pharmacology Model market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global In Vivo Pharmacology Model market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the In Vivo Pharmacology Model companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
NuChem Sciences Inc
Eurofins Discovery
Oncodesign Services
Jubilant Biosys
Pharmaron
Melior Discovery
NUVISAN GmbH
Porsolt
Sygnature Discovery
Aurigene Pharmaceutical Services Ltd
Reaction Biology
Addexbio
Paraza Pharma, Inc
Aragen Life Sciences Ltd
Dalriada
Biocytogen
Charles River Laboratories
Pharmacelsu
HitGen Inc
TCG Lifesciences
Segment by Type
Inflammation Animal Models
Pain and Neuroscience Animal Models
Diabetes and Metabolic Disorders Animal Models
Oncology Animal Models
Others
Segment by Application
Cardiovascular Diseases
Neurological Diseases
Autoimmune Diseases
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of In Vivo Pharmacology Model company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global In Vivo Pharmacology Model Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Inflammation Animal Models
1.2.3 Pain and Neuroscience Animal Models
1.2.4 Diabetes and Metabolic Disorders Animal Models
1.2.5 Oncology Animal Models
1.2.6 Others
1.3 Market by Application
1.3.1 Global In Vivo Pharmacology Model Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cardiovascular Diseases
1.3.3 Neurological Diseases
1.3.4 Autoimmune Diseases
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global In Vivo Pharmacology Model Market Perspective (2020-2031)
2.2 Global In Vivo Pharmacology Model Growth Trends by Region
2.2.1 Global In Vivo Pharmacology Model Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 In Vivo Pharmacology Model Historic Market Size by Region (2020-2025)
2.2.3 In Vivo Pharmacology Model Forecasted Market Size by Region (2026-2031)
2.3 In Vivo Pharmacology Model Market Dynamics
2.3.1 In Vivo Pharmacology Model Industry Trends
2.3.2 In Vivo Pharmacology Model Market Drivers
2.3.3 In Vivo Pharmacology Model Market Challenges
2.3.4 In Vivo Pharmacology Model Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top In Vivo Pharmacology Model Players by Revenue
3.1.1 Global Top In Vivo Pharmacology Model Players by Revenue (2020-2025)
3.1.2 Global In Vivo Pharmacology Model Revenue Market Share by Players (2020-2025)
3.2 Global In Vivo Pharmacology Model Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by In Vivo Pharmacology Model Revenue
3.4 Global In Vivo Pharmacology Model Market Concentration Ratio
3.4.1 Global In Vivo Pharmacology Model Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by In Vivo Pharmacology Model Revenue in 2024
3.5 Global Key Players of In Vivo Pharmacology Model Head office and Area Served
3.6 Global Key Players of In Vivo Pharmacology Model, Product and Application
3.7 Global Key Players of In Vivo Pharmacology Model, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 In Vivo Pharmacology Model Breakdown Data by Type
4.1 Global In Vivo Pharmacology Model Historic Market Size by Type (2020-2025)
4.2 Global In Vivo Pharmacology Model Forecasted Market Size by Type (2026-2031)
5 In Vivo Pharmacology Model Breakdown Data by Application
5.1 Global In Vivo Pharmacology Model Historic Market Size by Application (2020-2025)
5.2 Global In Vivo Pharmacology Model Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America In Vivo Pharmacology Model Market Size (2020-2031)
6.2 North America In Vivo Pharmacology Model Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America In Vivo Pharmacology Model Market Size by Country (2020-2025)
6.4 North America In Vivo Pharmacology Model Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe In Vivo Pharmacology Model Market Size (2020-2031)
7.2 Europe In Vivo Pharmacology Model Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe In Vivo Pharmacology Model Market Size by Country (2020-2025)
7.4 Europe In Vivo Pharmacology Model Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific In Vivo Pharmacology Model Market Size (2020-2031)
8.2 Asia-Pacific In Vivo Pharmacology Model Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2020-2025)
8.4 Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America In Vivo Pharmacology Model Market Size (2020-2031)
9.2 Latin America In Vivo Pharmacology Model Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America In Vivo Pharmacology Model Market Size by Country (2020-2025)
9.4 Latin America In Vivo Pharmacology Model Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa In Vivo Pharmacology Model Market Size (2020-2031)
10.2 Middle East & Africa In Vivo Pharmacology Model Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2020-2025)
10.4 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 NuChem Sciences Inc
11.1.1 NuChem Sciences Inc Company Details
11.1.2 NuChem Sciences Inc Business Overview
11.1.3 NuChem Sciences Inc In Vivo Pharmacology Model Introduction
11.1.4 NuChem Sciences Inc Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.1.5 NuChem Sciences Inc Recent Development
11.2 Eurofins Discovery
11.2.1 Eurofins Discovery Company Details
11.2.2 Eurofins Discovery Business Overview
11.2.3 Eurofins Discovery In Vivo Pharmacology Model Introduction
11.2.4 Eurofins Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.2.5 Eurofins Discovery Recent Development
11.3 Oncodesign Services
11.3.1 Oncodesign Services Company Details
11.3.2 Oncodesign Services Business Overview
11.3.3 Oncodesign Services In Vivo Pharmacology Model Introduction
11.3.4 Oncodesign Services Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.3.5 Oncodesign Services Recent Development
11.4 Jubilant Biosys
11.4.1 Jubilant Biosys Company Details
11.4.2 Jubilant Biosys Business Overview
11.4.3 Jubilant Biosys In Vivo Pharmacology Model Introduction
11.4.4 Jubilant Biosys Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.4.5 Jubilant Biosys Recent Development
11.5 Pharmaron
11.5.1 Pharmaron Company Details
11.5.2 Pharmaron Business Overview
11.5.3 Pharmaron In Vivo Pharmacology Model Introduction
11.5.4 Pharmaron Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.5.5 Pharmaron Recent Development
11.6 Melior Discovery
11.6.1 Melior Discovery Company Details
11.6.2 Melior Discovery Business Overview
11.6.3 Melior Discovery In Vivo Pharmacology Model Introduction
11.6.4 Melior Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.6.5 Melior Discovery Recent Development
11.7 NUVISAN GmbH
11.7.1 NUVISAN GmbH Company Details
11.7.2 NUVISAN GmbH Business Overview
11.7.3 NUVISAN GmbH In Vivo Pharmacology Model Introduction
11.7.4 NUVISAN GmbH Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.7.5 NUVISAN GmbH Recent Development
11.8 Porsolt
11.8.1 Porsolt Company Details
11.8.2 Porsolt Business Overview
11.8.3 Porsolt In Vivo Pharmacology Model Introduction
11.8.4 Porsolt Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.8.5 Porsolt Recent Development
11.9 Sygnature Discovery
11.9.1 Sygnature Discovery Company Details
11.9.2 Sygnature Discovery Business Overview
11.9.3 Sygnature Discovery In Vivo Pharmacology Model Introduction
11.9.4 Sygnature Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.9.5 Sygnature Discovery Recent Development
11.10 Aurigene Pharmaceutical Services Ltd
11.10.1 Aurigene Pharmaceutical Services Ltd Company Details
11.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
11.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Introduction
11.10.4 Aurigene Pharmaceutical Services Ltd Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.10.5 Aurigene Pharmaceutical Services Ltd Recent Development
11.11 Reaction Biology
11.11.1 Reaction Biology Company Details
11.11.2 Reaction Biology Business Overview
11.11.3 Reaction Biology In Vivo Pharmacology Model Introduction
11.11.4 Reaction Biology Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.11.5 Reaction Biology Recent Development
11.12 Addexbio
11.12.1 Addexbio Company Details
11.12.2 Addexbio Business Overview
11.12.3 Addexbio In Vivo Pharmacology Model Introduction
11.12.4 Addexbio Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.12.5 Addexbio Recent Development
11.13 Paraza Pharma, Inc
11.13.1 Paraza Pharma, Inc Company Details
11.13.2 Paraza Pharma, Inc Business Overview
11.13.3 Paraza Pharma, Inc In Vivo Pharmacology Model Introduction
11.13.4 Paraza Pharma, Inc Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.13.5 Paraza Pharma, Inc Recent Development
11.14 Aragen Life Sciences Ltd
11.14.1 Aragen Life Sciences Ltd Company Details
11.14.2 Aragen Life Sciences Ltd Business Overview
11.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Model Introduction
11.14.4 Aragen Life Sciences Ltd Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.14.5 Aragen Life Sciences Ltd Recent Development
11.15 Dalriada
11.15.1 Dalriada Company Details
11.15.2 Dalriada Business Overview
11.15.3 Dalriada In Vivo Pharmacology Model Introduction
11.15.4 Dalriada Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.15.5 Dalriada Recent Development
11.16 Biocytogen
11.16.1 Biocytogen Company Details
11.16.2 Biocytogen Business Overview
11.16.3 Biocytogen In Vivo Pharmacology Model Introduction
11.16.4 Biocytogen Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.16.5 Biocytogen Recent Development
11.17 Charles River Laboratories
11.17.1 Charles River Laboratories Company Details
11.17.2 Charles River Laboratories Business Overview
11.17.3 Charles River Laboratories In Vivo Pharmacology Model Introduction
11.17.4 Charles River Laboratories Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.17.5 Charles River Laboratories Recent Development
11.18 Pharmacelsu
11.18.1 Pharmacelsu Company Details
11.18.2 Pharmacelsu Business Overview
11.18.3 Pharmacelsu In Vivo Pharmacology Model Introduction
11.18.4 Pharmacelsu Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.18.5 Pharmacelsu Recent Development
11.19 HitGen Inc
11.19.1 HitGen Inc Company Details
11.19.2 HitGen Inc Business Overview
11.19.3 HitGen Inc In Vivo Pharmacology Model Introduction
11.19.4 HitGen Inc Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.19.5 HitGen Inc Recent Development
11.20 TCG Lifesciences
11.20.1 TCG Lifesciences Company Details
11.20.2 TCG Lifesciences Business Overview
11.20.3 TCG Lifesciences In Vivo Pharmacology Model Introduction
11.20.4 TCG Lifesciences Revenue in In Vivo Pharmacology Model Business (2020-2025)
11.20.5 TCG Lifesciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global In Vivo Pharmacology Model Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Inflammation Animal Models
Table 3. Key Players of Pain and Neuroscience Animal Models
Table 4. Key Players of Diabetes and Metabolic Disorders Animal Models
Table 5. Key Players of Oncology Animal Models
Table 6. Key Players of Others
Table 7. Global In Vivo Pharmacology Model Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global In Vivo Pharmacology Model Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global In Vivo Pharmacology Model Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global In Vivo Pharmacology Model Market Share by Region (2020-2025)
Table 11. Global In Vivo Pharmacology Model Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global In Vivo Pharmacology Model Market Share by Region (2026-2031)
Table 13. In Vivo Pharmacology Model Market Trends
Table 14. In Vivo Pharmacology Model Market Drivers
Table 15. In Vivo Pharmacology Model Market Challenges
Table 16. In Vivo Pharmacology Model Market Restraints
Table 17. Global In Vivo Pharmacology Model Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global In Vivo Pharmacology Model Market Share by Players (2020-2025)
Table 19. Global Top In Vivo Pharmacology Model Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in In Vivo Pharmacology Model as of 2024)
Table 20. Ranking of Global Top In Vivo Pharmacology Model Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by In Vivo Pharmacology Model Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of In Vivo Pharmacology Model, Headquarters and Area Served
Table 23. Global Key Players of In Vivo Pharmacology Model, Product and Application
Table 24. Global Key Players of In Vivo Pharmacology Model, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global In Vivo Pharmacology Model Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global In Vivo Pharmacology Model Revenue Market Share by Type (2020-2025)
Table 28. Global In Vivo Pharmacology Model Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global In Vivo Pharmacology Model Revenue Market Share by Type (2026-2031)
Table 30. Global In Vivo Pharmacology Model Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global In Vivo Pharmacology Model Revenue Market Share by Application (2020-2025)
Table 32. Global In Vivo Pharmacology Model Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global In Vivo Pharmacology Model Revenue Market Share by Application (2026-2031)
Table 34. North America In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America In Vivo Pharmacology Model Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America In Vivo Pharmacology Model Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe In Vivo Pharmacology Model Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe In Vivo Pharmacology Model Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific In Vivo Pharmacology Model Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America In Vivo Pharmacology Model Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America In Vivo Pharmacology Model Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2026-2031) & (US$ Million)
Table 49. NuChem Sciences Inc Company Details
Table 50. NuChem Sciences Inc Business Overview
Table 51. NuChem Sciences Inc In Vivo Pharmacology Model Product
Table 52. NuChem Sciences Inc Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 53. NuChem Sciences Inc Recent Development
Table 54. Eurofins Discovery Company Details
Table 55. Eurofins Discovery Business Overview
Table 56. Eurofins Discovery In Vivo Pharmacology Model Product
Table 57. Eurofins Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 58. Eurofins Discovery Recent Development
Table 59. Oncodesign Services Company Details
Table 60. Oncodesign Services Business Overview
Table 61. Oncodesign Services In Vivo Pharmacology Model Product
Table 62. Oncodesign Services Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 63. Oncodesign Services Recent Development
Table 64. Jubilant Biosys Company Details
Table 65. Jubilant Biosys Business Overview
Table 66. Jubilant Biosys In Vivo Pharmacology Model Product
Table 67. Jubilant Biosys Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 68. Jubilant Biosys Recent Development
Table 69. Pharmaron Company Details
Table 70. Pharmaron Business Overview
Table 71. Pharmaron In Vivo Pharmacology Model Product
Table 72. Pharmaron Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 73. Pharmaron Recent Development
Table 74. Melior Discovery Company Details
Table 75. Melior Discovery Business Overview
Table 76. Melior Discovery In Vivo Pharmacology Model Product
Table 77. Melior Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 78. Melior Discovery Recent Development
Table 79. NUVISAN GmbH Company Details
Table 80. NUVISAN GmbH Business Overview
Table 81. NUVISAN GmbH In Vivo Pharmacology Model Product
Table 82. NUVISAN GmbH Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 83. NUVISAN GmbH Recent Development
Table 84. Porsolt Company Details
Table 85. Porsolt Business Overview
Table 86. Porsolt In Vivo Pharmacology Model Product
Table 87. Porsolt Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 88. Porsolt Recent Development
Table 89. Sygnature Discovery Company Details
Table 90. Sygnature Discovery Business Overview
Table 91. Sygnature Discovery In Vivo Pharmacology Model Product
Table 92. Sygnature Discovery Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 93. Sygnature Discovery Recent Development
Table 94. Aurigene Pharmaceutical Services Ltd Company Details
Table 95. Aurigene Pharmaceutical Services Ltd Business Overview
Table 96. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product
Table 97. Aurigene Pharmaceutical Services Ltd Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 98. Aurigene Pharmaceutical Services Ltd Recent Development
Table 99. Reaction Biology Company Details
Table 100. Reaction Biology Business Overview
Table 101. Reaction Biology In Vivo Pharmacology Model Product
Table 102. Reaction Biology Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 103. Reaction Biology Recent Development
Table 104. Addexbio Company Details
Table 105. Addexbio Business Overview
Table 106. Addexbio In Vivo Pharmacology Model Product
Table 107. Addexbio Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 108. Addexbio Recent Development
Table 109. Paraza Pharma, Inc Company Details
Table 110. Paraza Pharma, Inc Business Overview
Table 111. Paraza Pharma, Inc In Vivo Pharmacology Model Product
Table 112. Paraza Pharma, Inc Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 113. Paraza Pharma, Inc Recent Development
Table 114. Aragen Life Sciences Ltd Company Details
Table 115. Aragen Life Sciences Ltd Business Overview
Table 116. Aragen Life Sciences Ltd In Vivo Pharmacology Model Product
Table 117. Aragen Life Sciences Ltd Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 118. Aragen Life Sciences Ltd Recent Development
Table 119. Dalriada Company Details
Table 120. Dalriada Business Overview
Table 121. Dalriada In Vivo Pharmacology Model Product
Table 122. Dalriada Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 123. Dalriada Recent Development
Table 124. Biocytogen Company Details
Table 125. Biocytogen Business Overview
Table 126. Biocytogen In Vivo Pharmacology Model Product
Table 127. Biocytogen Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 128. Biocytogen Recent Development
Table 129. Charles River Laboratories Company Details
Table 130. Charles River Laboratories Business Overview
Table 131. Charles River Laboratories In Vivo Pharmacology Model Product
Table 132. Charles River Laboratories Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 133. Charles River Laboratories Recent Development
Table 134. Pharmacelsu Company Details
Table 135. Pharmacelsu Business Overview
Table 136. Pharmacelsu In Vivo Pharmacology Model Product
Table 137. Pharmacelsu Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 138. Pharmacelsu Recent Development
Table 139. HitGen Inc Company Details
Table 140. HitGen Inc Business Overview
Table 141. HitGen Inc In Vivo Pharmacology Model Product
Table 142. HitGen Inc Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 143. HitGen Inc Recent Development
Table 144. TCG Lifesciences Company Details
Table 145. TCG Lifesciences Business Overview
Table 146. TCG Lifesciences In Vivo Pharmacology Model Product
Table 147. TCG Lifesciences Revenue in In Vivo Pharmacology Model Business (2020-2025) & (US$ Million)
Table 148. TCG Lifesciences Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. In Vivo Pharmacology Model Picture
Figure 2. Global In Vivo Pharmacology Model Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global In Vivo Pharmacology Model Market Share by Type: 2024 VS 2031
Figure 4. Inflammation Animal Models Features
Figure 5. Pain and Neuroscience Animal Models Features
Figure 6. Diabetes and Metabolic Disorders Animal Models Features
Figure 7. Oncology Animal Models Features
Figure 8. Others Features
Figure 9. Global In Vivo Pharmacology Model Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global In Vivo Pharmacology Model Market Share by Application: 2024 VS 2031
Figure 11. Cardiovascular Diseases Case Studies
Figure 12. Neurological Diseases Case Studies
Figure 13. Autoimmune Diseases Case Studies
Figure 14. Others Case Studies
Figure 15. In Vivo Pharmacology Model Report Years Considered
Figure 16. Global In Vivo Pharmacology Model Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global In Vivo Pharmacology Model Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global In Vivo Pharmacology Model Market Share by Region: 2024 VS 2031
Figure 19. Global In Vivo Pharmacology Model Market Share by Players in 2024
Figure 20. Global Top In Vivo Pharmacology Model Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in In Vivo Pharmacology Model as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by In Vivo Pharmacology Model Revenue in 2024
Figure 22. North America In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America In Vivo Pharmacology Model Market Share by Country (2020-2031)
Figure 24. United States In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe In Vivo Pharmacology Model Market Share by Country (2020-2031)
Figure 28. Germany In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific In Vivo Pharmacology Model Market Share by Region (2020-2031)
Figure 36. China In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America In Vivo Pharmacology Model Market Share by Country (2020-2031)
Figure 44. Mexico In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa In Vivo Pharmacology Model Market Share by Country (2020-2031)
Figure 48. Turkey In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE In Vivo Pharmacology Model Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. NuChem Sciences Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 52. Eurofins Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 53. Oncodesign Services Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 54. Jubilant Biosys Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 55. Pharmaron Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 56. Melior Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 57. NUVISAN GmbH Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 58. Porsolt Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 59. Sygnature Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 60. Aurigene Pharmaceutical Services Ltd Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 61. Reaction Biology Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 62. Addexbio Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 63. Paraza Pharma, Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 64. Aragen Life Sciences Ltd Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 65. Dalriada Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 66. Biocytogen Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 67. Charles River Laboratories Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 68. Pharmacelsu Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 69. HitGen Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 70. TCG Lifesciences Revenue Growth Rate in In Vivo Pharmacology Model Business (2020-2025)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
